{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-092566","form_type":"8-K","ticker":"VYGR","cik":"0001640266","company_name":"Voyager Therapeutics, Inc.","filed_at":"2023-08-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.650516+00:00","generated_at":"2026-06-11T08:29:01.154177+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Voyager Therapeutics expands leased space by ~61k SF; annual rent ~$4.9M starting June 2024","bullets":["Total leased premises grows to 93,449 rentable SF (from ~32k SF) with addition of third floor.","Expansion rent commences June 2024 at $4,873,906.50 annual base rent, escalating ~3% annually through Jan 2031.","Landlord provides up to $1,839,210 tenant improvement allowance; tenant covers excess costs.","Security deposit letter of credit increased from ~$1.04M to ~$2.26M as of Jan 1, 2024.","Parking allocated to tenant increases from 75 to 228 spaces upon expansion commencement."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-092566","json":"https://secwatch.observer/filing/0001104659-23-092566.json","markdown":"https://secwatch.observer/filing/0001104659-23-092566.md","text":"https://secwatch.observer/filing/0001104659-23-092566.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1640266/000110465923092566/0001104659-23-092566-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1640266/000110465923092566/tm2323892d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T08:29:01.154177+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"555b1b408721e9432657bdd5c5dba8750d6fd84c","claim":"Voyager Therapeutics, Inc. amended lease obligation of Annual base rent of approximately $4.9 million increasing annually by approximately 3%; total commitment of ~$2.3 millio with LS 75 Hayden, LLC at Not applicable (lease) maturing January 31, 2031.","evidence_excerpt":"mendment”) to its existing lease agreement with LS 75 Hayden, LLC, as successor in interest to HCP/King 75 Hayden LLC (the “Landlord”),","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465923092566/0001104659-23-092566-index.htm","confidence":0.95,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"lease obligation"},{"label":"Principal","value":"Annual base rent of approximately $4.9 million increasing annually by approximately 3%; total commitment of ~$2.3 millio"},{"label":"Counterparty","value":"LS 75 Hayden, LLC"},{"label":"Rate","value":"Not applicable (lease)"},{"label":"Maturity","value":"January 31, 2031"},{"label":"Event","value":"amendment"}],"fact_type":"debt_financing"},{"claim_id":"158e7577e89d2df0187e70a9133a318bb45d8343","claim":"Voyager Therapeutics, Inc. amended Lease Agreement with LS 75 Hayden, LLC (effective 2023-08-11).","evidence_excerpt":"On August 11, 2023, Voyager Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a first amendment (the “First Amendment”) to its existing lease agreement with LS 75 Hayden, LLC, as successor in interest to HCP/King 75 Hayden LLC (the “Landlord”), dated March 16, 2020 (the “Lease Agreement”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465923092566/0001104659-23-092566-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"lease"},{"label":"Counterparty","value":"LS 75 Hayden, LLC"},{"label":"Effective","value":"2023-08-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}